These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 34570010)

  • 1. Antibody therapy for COVID-19.
    Hammarström L; Marcotte H; Piralla A; Baldanti F; Pan-Hammarström Q
    Curr Opin Allergy Clin Immunol; 2021 Dec; 21(6):553-558. PubMed ID: 34570010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
    Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
    Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Hyperimmune Immunoglobulin Demonstrates Potent Neutralization and Antibody-Dependent Cellular Cytotoxicity and Phagocytosis Through N and S Proteins.
    Díez JM; Romero C; Cruz M; Vandeberg P; Merritt WK; Pradenas E; Trinité B; Blanco J; Clotet B; Willis T; Gajardo R
    J Infect Dis; 2022 Mar; 225(6):938-946. PubMed ID: 34693968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison study of SARS-CoV-2 IgG antibody between male and female COVID-19 patients: A possible reason underlying different outcome between sex.
    Zeng F; Dai C; Cai P; Wang J; Xu L; Li J; Hu G; Wang Z; Zheng F; Wang L
    J Med Virol; 2020 Oct; 92(10):2050-2054. PubMed ID: 32383183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Production of anti-SARS-CoV-2 hyperimmune globulin from convalescent plasma.
    Vandeberg P; Cruz M; Diez JM; Merritt WK; Santos B; Trukawinski S; Wellhouse A; Jose M; Willis T
    Transfusion; 2021 Jun; 61(6):1705-1709. PubMed ID: 33715160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Convalescent plasma for pediatric patients with SARS-CoV-2-associated acute respiratory distress syndrome.
    Diorio C; Anderson EM; McNerney KO; Goodwin EC; Chase JC; Bolton MJ; Arevalo CP; Weirick ME; Gouma S; Vella LA; Henrickson SE; Chiotos K; Fitzgerald JC; Kilbaugh TJ; John ARO; Blatz AM; Lambert MP; Sullivan KE; Tartaglione MR; Zambrano D; Martin M; Lee JH; Young P; Friedman D; Sesok-Pizzini DA; Hensley SE; Behrens EM; Bassiri H; Teachey DT
    Pediatr Blood Cancer; 2020 Nov; 67(11):e28693. PubMed ID: 32885904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SARS-CoV-2 Neutralizing Antibody Responses towards Full-Length Spike Protein and the Receptor-Binding Domain.
    Bayarri-Olmos R; Idorn M; Rosbjerg A; Pérez-Alós L; Hansen CB; Johnsen LB; Helgstrand C; Zosel F; Bjelke JR; Öberg FK; Søgaard M; Paludan SR; Bak-Thomsen T; Jardine JG; Skjoedt MO; Garred P
    J Immunol; 2021 Aug; 207(3):878-887. PubMed ID: 34301847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential therapeutic options for COVID-19: an update on current evidence.
    Niknam Z; Jafari A; Golchin A; Danesh Pouya F; Nemati M; Rezaei-Tavirani M; Rasmi Y
    Eur J Med Res; 2022 Jan; 27(1):6. PubMed ID: 35027080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural Analysis of Neutralizing Epitopes of the SARS-CoV-2 Spike to Guide Therapy and Vaccine Design Strategies.
    Finkelstein MT; Mermelstein AG; Parker Miller E; Seth PC; Stancofski ED; Fera D
    Viruses; 2021 Jan; 13(1):. PubMed ID: 33477902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody response and therapy in COVID-19 patients: what can be learned for vaccine development?
    Lu L; Zhang H; Zhan M; Jiang J; Yin H; Dauphars DJ; Li SY; Li Y; He YW
    Sci China Life Sci; 2020 Dec; 63(12):1833-1849. PubMed ID: 33355886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7.
    Wang P; Nair MS; Liu L; Iketani S; Luo Y; Guo Y; Wang M; Yu J; Zhang B; Kwong PD; Graham BS; Mascola JR; Chang JY; Yin MT; Sobieszczyk M; Kyratsous CA; Shapiro L; Sheng Z; Huang Y; Ho DD
    Nature; 2021 May; 593(7857):130-135. PubMed ID: 33684923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Passive immune therapies: another tool against COVID-19.
    Estcourt LJ
    Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):628-641. PubMed ID: 34889410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SARS-CoV-2-specific humoral and cellular immunity in two renal transplants and two hemodialysis patients treated with convalescent plasma.
    Lindemann M; Krawczyk A; Dolff S; Konik M; Rohn H; Platte M; Thümmler L; Schwarzkopf S; Schipper L; Bormann M; van de Sand L; Breyer M; Klump H; Knop D; Lenz V; Temme C; Dittmer U; Horn PA; Witzke O
    J Med Virol; 2021 May; 93(5):3047-3054. PubMed ID: 33527424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Passive immunization and its rebirth in the era of the COVID-19 pandemic.
    Pavia CS; Wormser GP
    Int J Antimicrob Agents; 2021 Mar; 57(3):106275. PubMed ID: 33400975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Convalescent plasma therapy for the treatment of patients with COVID-19: Assessment of methods available for antibody detection and their correlation with neutralising antibody levels.
    Harvala H; Robb ML; Watkins N; Ijaz S; Dicks S; Patel M; Supasa P; Wanwisa D; Liu C; Mongkolsapaya J; Bown A; Bailey D; Vipond R; Grayson N; Temperton N; Gupta S; Ploeg RJ; Bolton J; Fyfe A; Gopal R; Simmonds P; Screaton G; Thompson C; Brooks T; Zambon M; Miflin G; Roberts DJ
    Transfus Med; 2021 Jun; 31(3):167-175. PubMed ID: 33333627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Administration of high titer convalescent anti-SARS-CoV-2 plasma: From donor selection to monitoring recipient outcomes.
    Mendoza RP; Fyke W; Daniel D; Gabutan E; Das B; Bajaj H; Easy M; Vasileva A; Colbourn R; Alawad M; Dehghani A; Lin B; Emechebe D; Patel P; Jabbar A; Nikolov DB; Giovaniello D; Kang S; Tatem L; Bromberg K; Augenbraun M; Premsrirut P; Libien J; Norin AJ
    Hum Immunol; 2021 Apr; 82(4):255-263. PubMed ID: 33640208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutralizing antibody: a savior in the Covid-19 disease.
    Gupta SL; Jaiswal RK
    Mol Biol Rep; 2022 Mar; 49(3):2465-2474. PubMed ID: 34988889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Understanding neutralising antibodies against SARS-CoV-2 and their implications in clinical practice.
    Pang NY; Pang AS; Chow VT; Wang DY
    Mil Med Res; 2021 Aug; 8(1):47. PubMed ID: 34465396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review.
    Piechotta V; Chai KL; Valk SJ; Doree C; Monsef I; Wood EM; Lamikanra A; Kimber C; McQuilten Z; So-Osman C; Estcourt LJ; Skoetz N
    Cochrane Database Syst Rev; 2020 Jul; 7(7):CD013600. PubMed ID: 32648959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High neutralizing potency of swine glyco-humanized polyclonal antibodies against SARS-CoV-2.
    Vanhove B; Duvaux O; Rousse J; Royer PJ; Evanno G; Ciron C; Lheriteau E; Vacher L; Gervois N; Oger R; Jacques Y; Conchon S; Salama A; Duchi R; Lagutina I; Perota A; Delahaut P; Ledure M; Paulus M; So RT; Mok CK; Bruzzone R; Bouillet M; Brouard S; Cozzi E; Galli C; Blanchard D; Bach JM; Soulillou JP
    Eur J Immunol; 2021 Jun; 51(6):1412-1422. PubMed ID: 33576494
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.